01/2022-now, Institute of Zoology, Chinese Academy of Sciences, Associate professor

07/2020-12/2021, Bioland Lab, Associate professor

07/2018-06/2020, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Post doctor

09/2012-06/2018, University of Science and Technology of China, Ph.D

09/2008-07/2012, Xinyang Normal University, Bachelor

Regeneration of immune and hematopoietic cells from pluripotent stem cells. Cell therapy and anti-tumor research of regenerated cells.

1. General Program of National Natural Science Foundation of China
2. Youth Program of National Natural Science Foundation of China
3. National Key Research and Development Project

1. Wang, Z., L. Zhang, D. Huang, C. Xia, Q. Weng, Y. Lin, Y. Liu, Z. Liu, R. Yi, F. Zhang, Y. Zhao, J. Wu, H. Qi, L. Liu, Y. Shen, Y. Chen, Y. Zhu, T. Wang, M. Zhang, F. Hu and J. Wang (2026). "Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models." Cell Stem Cell. (Co-corresponding)

2. Lin, Y., Z. Xiao, F. Hu, X. Zheng, C. Zhang, Y. Wang, Y. Liu, D. Huang, Z. Wang, C. Xia, Q. Weng, L. Zhang, Y. Zhao, H. Qi, Y. Shen, Y. Chen, F. Zhang, J. Wu, P. Liu, J. Xu, L. Liu, Y. Zhu, J. Zhang, W. Qian, A. Liang, X. Zhu, T. Wang, M. Zhang and J. Wang (2025). "Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies." J Hematol Oncol 18(1): 57. (Co-corresponding)

3. Zhang, Q., C. Xia, Q. Weng, L. Zhang, Y. Wang, Y. Liu, X. Zheng, Y. Lin, Y. Chen, Y. Shen, H, Qi, L. Liu, Y. Zhu, M. Zhang, D. Huang, F. Hu, M. Zhang, H. Zeng, J. Wang and T. Wang (2024). "Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals." Front Immunol 15:1504459. (Corresponding author)

4. Liu, Y., M. Zhang, X. Shen, C. Xia, F. Hu, D. Huang, Q. Weng, Q. Zhang, L. Liu, Y. Zhu, L. Wang, J. Hao, M. Zhang, T. Wang and J. Wang (2024). "Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals." Cell Prolif 57(12): e13727. (Co-corresponding)

5. Wang, T., C. Xia, Q. Weng, K. Wang, Y. Dong, S. Hao, F. Dong, X. Liu, L. Liu, Y. Geng, Y. Guan, J. Du, T. Cheng, H. Cheng and J. Wang (2022). "Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway." Haematologica 107(1): 154-166. (First author)

6. Xia, C., T. Wang, H. Cheng, Y. Dong, Q. Weng, G. Sun, P. Zhou, K. Wang, X. Liu, Y. Geng, S. Ma, S. Hao, L. Xu, Y. Guan, J. Du, X. Du, Y. Li, X. Zhu, Y. Shi, S. Xu, D. Wang, T. Cheng and J. Wang (2020). "Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment." Leukemia 34(9): 2375-2383. (Co-first author)

7. Wang, T., C. Lv, F. Hu, L. Liu and J. Wang (2020). "Two-step protocol for regeneration of immunocompetent T cells from mouse pluripotent stem cells." Blood Sci 2(3): 79-88. (First author)

8. Wang, T., C. Xia, Y. Dong, X. Chen, J. Wang and J. Du (2018). "Trim27 confers myeloid hematopoiesis competitiveness by up-regulating myeloid master genes." J Leukoc Biol 104(4): 799-809. (First author)

9. Wang, T., C. Li, C. Xia, Y. Dong, D. Yang, Y. Geng, J. Cai, J. Zhang, X. Zhang and J. Wang (2015). "Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo." Am J Transl Res 7(10): 1963-1973. (First author)